ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Clinical trials for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with aggressive blood cancers
Disease control OngoingThis early-stage study is testing a new drug called uproleselan, given with two standard chemotherapy drugs, for children and teenagers with aggressive forms of leukemia that have come back or stopped responding to treatment. The main goals are to find the safest dose and see how…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists test drug combo to fight tough blood cancer
Disease control OngoingThis study is testing if adding a drug called pomalidomide to standard chemotherapy works better for adults newly diagnosed with a specific, harder-to-treat type of acute myeloid leukemia (AML). About 50 participants will be randomly assigned to receive either the standard chemo …
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Immune-Boosting drug joins fight against tough blood cancer in seniors
Disease control OngoingThis study is testing if adding an immunotherapy drug (pembrolizumab) to a standard two-drug combination works better for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The goal is to see if the three-drug combo helps more p…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New pill trial targets genetic flaw in tough blood cancers
Disease control OngoingThis study is testing if a pill called olaparib can help control advanced blood cancers (acute myeloid leukemia or myelodysplastic syndrome) that have come back or haven't responded to standard treatments. It is for adults whose cancer has a specific genetic change called an IDH …
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for AML patients: can a Cancer-Fighting drug boost Chemo's power?
Disease control OngoingThis study is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combination helps more patients achieve a deep remission with no detectable cancer ce…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists test new drug cocktail in fight against tough blood cancer
Disease control OngoingThis early-stage study is testing a combination of three drugs—bortezomib, sorafenib, and decitabine—to treat acute myeloid leukemia (AML). The main goal is to find the safest and most effective dose. The study is for adults with AML who are older, have a type that is hard to tre…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC